Phenotype to genotype: dissecting meningococcal disease and carriage traits
Phenotype to genotype: dissecting meningococcal disease and carriage traits
批准号:
MR/S009264/1
负责人:
Christopher Bayliss
金额:
$80.44万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2019
资助国家:
英国
项目状态:
已结题
起止时间:
2019 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Bacteria cause disease by combining multiple different behaviours. Neisseria meningitidis, the meningococcus, causes both meningitis and septicaemia. In 2016-2017, there were 747 confirmed meningococcal disease cases in England despite new meningococcal vaccines being introduced into the infant and teenage immunisation schedules. In order to cause disease, the meningococcus first transmits from one person to another and then sticks to tissues at the back of the throat and around the tonsils. The bacterium survives for multiple days avoiding effector molecules produced by our bodies such as antibodies. Disease occurs when the organism invades by moving from the mucosal tissues into the blood where the bacterial cells grow rapidly and resist being killed by complement and white blood cells. From the blood, this fearsome pathogen spreads and causes inflammation in the tissues lining the brain. Each step of the disease process is mediated by combinations of molecules or virulence factors encoded in the genomes of meningococcal bacteria. Currently, we know that the capsule (polysaccharides present on the outside of bacterial cells) and several other factors are required for meningococci to cause disease. But we also have large amounts of information about the genomes of 1,000s of meningococcal disease and carriage isolates. These genomes contain extensive information about identities of disease-causing strains, how strains change over time and on numbers/types of genes present in each strain. While these genomes have enabled us to link certain sequences to the disease state, there has only been limited efforts to link genomic variation to variation in the phenotypes required for disease so that much of our current information is inferential rather than experimentally-based. We intend to explore phenotype-to-genotype links by testing up to ~330 isolates in a series of 12 assays that mimic various disease and carriage behaviours. We will develop high throughput assays, enabling rapid processing of multiple isolates, and utilise these methodologies to study endemic serogroup Y and hyperinvasive serogroup W meningococcal isolates from patients and carriers. Quantitative outputs from multiple phenotypes will provide us with significant power for statistical association tests to link phenotypes to disease and carriage traits and to identify specific genetic determinants of these traits. These tests will be followed up by molecular testing of specific genetic determinants to confirm their contributions to a specific behaviour. This step will involve construction of mutants with alterations in a single gene or in multiple genes so that we can see how combinations of phenotypes contribute to disease processes.We will also explore interactions between virulent and avirulent variants. We have already observed that isolates from one carrier had opposing and potentially antagonistic behaviours with one causing disruption of monolayers of human cells while the other tightened interactions between these cells. We will test whether these bacterial variants antagonise each other and if this is a general phenomenon affecting multiple isolates and other disease phenotypes.What we hope to gain is not only a better understanding of how meningococci cause disease but also improved assessment of the prevalence of disease-attributes of meningococcal strains. This will be important as we monitor the impact of the new MenB vaccine, Bexsero, on disease in the UK as avoidance of vaccine responses could occur by either changes in vaccine-targeted antigens or enhanced virulence. Our information will also facilitate development of second generation vaccines by identifying key determinants of disease for inclusion in new vaccines. Finally, our approaches will be applicable to other bacterial pathogens enhancing translation of genotypes into phenotypes for the ever-expanding genomic databases of pathogenic bacteria.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1371/journal.pgen.1009829
发表时间:
2021-09
期刊:
PLoS genetics
影响因子:
4.5
作者:
[Calland JK, Pascoe B, Bayliss SC, Mourkas E, Berthenet E, Thorpe HA, Hitchings MD, Feil EJ, Corander J, Blaser MJ, Falush D, Sheppard SK]
通讯作者:
Sheppard SK
DOI:
10.1099/mgen.0.001114
发表时间:
2023-10
期刊:
Microbial genomics
影响因子:
3.9
作者:
[Monteith W, Pascoe B, Mourkas E, Clark J, Hakim M, Hitchings MD, McCarthy N, Yahara K, Asakura H, Sheppard SK]
通讯作者:
Sheppard SK
DOI:
10.1016/j.vaccine.2020.08.031
发表时间:
2020-11-17
期刊:
Vaccine
影响因子:
5.5
作者:
[Findlow J, Bayliss CD, Beernink PT, Borrow R, Liberator P, Balmer P]
通讯作者:
Balmer P
Assessing Mechanisms for Delivery of COVID-19 Vaccines to University Students
-
批准号:ES/W00299X/1
-
项目类别:Research Grant
-
资助金额:$7.88万
-
财政年份:2021
-
负责人:Christopher Bayliss
-
依托单位:
Analysing the phase variable genes of Campylobacter jejuni - tools for novel diagnostics and vaccines
-
批准号:BB/M029352/1
-
项目类别:Research Grant
-
资助金额:$1.42万
-
财政年份:2015
-
负责人:Christopher Bayliss
-
依托单位:
MICA: Does phase variation contribute to virulence and immune evasion of Neisseria meningitidis?
-
批准号:MR/M020193/1
-
项目类别:Research Grant
-
资助金额:$56.34万
-
财政年份:2015
-
负责人:Christopher Bayliss
-
依托单位:
Campylobacter phase variation and its impact on immunity and vaccine development.
-
批准号:BB/I024712/1
-
项目类别:Research Grant
-
资助金额:$11.82万
-
财政年份:2012
-
负责人:Christopher Bayliss
-
依托单位:
国内基金
海外基金
登录
查看更多内容
人大肠癌SP细胞干性表型和基因型分析
-
批准号:81101870
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2011
-
负责人:胡均
-
依托单位:
DARC在基底细胞样乳腺癌中作用机制的研究
-
批准号:81001172
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2010
-
负责人:王杰
-
依托单位:
蛋鸡啄羽相残行为的研究:基于社会性气味识别的控制对策
-
批准号:30770289
-
项目类别:面上项目
-
资助金额:8.0万元
-
批准年份:2007
-
负责人:赵亚军
-
依托单位:
不同基因型蛔虫宿主特异性差异和“猪型蛔虫-猪”、“人型蛔虫-猪”实验模型的建立
-
批准号:30560139
-
项目类别:地区科学基金项目
-
资助金额:24.0万元
-
批准年份:2005
-
负责人:彭卫东
-
依托单位: